BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 29, 2004
View Archived Issues
Merck researchers claim new tyrosine kinase regulators and their use
Read More
Novel 5-HT receptor ligands with utility in psychotic conditions
Read More
New glucokinase activators emerge from Roche R&D
Read More
Pfizer scientists design novel cannabinoid CB1 antagonists for obesity and alcohol and tobacco abuse
Read More
Novel dopamine D3 agonists and their use in sexual disorders
Read More
Novartis presents new VEGF inhibitors for cancer and ocular disorders
Read More
Novel propapoptotic agents newly developed at Aponetics
Read More
HIV-1 integrase inhibitor promising against resistant viral strains
Read More
Nonnucleoside adenosine deaminase inhibitor shows antiinflammatory activity in vivo
Read More
Promising nonpeptide BACE inhibitor decreases the formation of amyloid plaques in vivo
Read More
Approval for new liquid formulation of Synagis
Read More
Enrollment completed in STELLAR 2 trial of Xyotax
Read More
Celera Genomics receives cathepsin K milestone from Merck
Read More
APD-356 enters phase Ib study for obesity
Read More
Boston Life Sciences files IND for phase I study of Axosine
Read More
Enrollment completed in phase I/II study of GA-GCB for Gaucher's disease
Read More
Abbott seeks approval of once-daily Kaletra in U.S., E.U.
Read More
KOS-862 enters phase Ib trial in combination with Paraplatin for solid tumors
Read More
New phase II study of Titan's DITPA for CHF
Read More
Y's Therapeutics files in begin European phase II studies of YS-IL6 and YS-TH2
Read More
Combination regimens in the treatment of CTCL
Read More
Phase Ib study of TACI-Ig in SLE
Read More
Survival benefits of Canvaxin in metastatic melanoma
Read More
Locus and P&G collaborate on diabetes drug design
Read More
Phase I trial of ON-01910Na commences enrollment
Read More
Agensys enters collaboration and license agreement with Genentech
Read More
Phase II study of Theratope for metastatic breast cancer completes enrollment
Read More
Clinical study cleared to begin of HGF plasmid for ischemic heart disease
Read More